1. Outcomes following infrapopliteal angioplasty for critical limb ischemia
- Author
-
Rodney P. Bensley, Ruby C. Lo, Allen D. Hamdan, Mark C. Wyers, Jeremy D. Darling, Suzanne E. Dahlberg, Kristina A. Giles, and Marc L. Schermerhorn
- Subjects
Adult ,Male ,medicine.medical_specialty ,Percutaneous ,Critical Illness ,medicine.medical_treatment ,Revascularization ,Article ,Restenosis ,Ischemia ,Angioplasty ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Leg ,business.industry ,Hazard ratio ,Perioperative ,Critical limb ischemia ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,Amputation ,Female ,medicine.symptom ,business ,Cardiology and Cardiovascular Medicine - Abstract
Objective Infrapopliteal angioplasty (percutaneous transluminal angioplasty [PTA]) is routinely used to treat critical limb ischemia (CLI) despite limited data on long-term outcomes. Methods We reviewed all patients undergoing infrapopliteal PTA for CLI from 2004 to 2012 stratified by TransAtlantic Inter-Society Consensus (TASC) class. Outcomes included restenosis, primary patency, reintervention (w/PTA or bypass), amputation, procedural complications, wound healing, and survival. Results Infrapopliteal PTA (stenting 14%, multilevel intervention 50%) was performed in 459 limbs of 413 patients (59% male) with a technical success of 93% and perioperative complications in 11%. TASC class was 16% A, 22% B, 27% C, and 34% D. Multilevel interventions were performed in 50% of limbs and were evenly distributed among all TASC classes. All technical failures were TASC D lesions. Mean follow-up was 15 months; 5-year survival was 49%. One- and 5-year primary patency was 57% and 38% and limb salvage was 84% and 81%, respectively. Restenosis was associated with TASC C (hazard ratio [HR], 2.2; 95% CI, 1.2-3.9; P = .010) and TASC D (HR, 2.4; 95% CI, 1.3-4.4; P = .004) lesions. Amputation rates were higher in patients who were not candidates for bypass (HR, 4.4; 95% CI, 2.6-7.5; P P = .03). Unsuitability for bypass was also predictive of repeat PTA (HR, 1.8; 95% CI, 1.0-3.4; P = .047). Postoperative clopidogrel use was associated with lower rates of any revascularization (HR, 0.46; 95% CI, 0.25-0.83; P = .011). Conclusions Infrapopliteal PTA is effective primary therapy for TASC A, B, and C lesions. Surgical bypass should be offered to patients with TASC D disease who are suitable candidates. Multilevel intervention does not adversely affect outcome.
- Published
- 2013
- Full Text
- View/download PDF